Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

Journal of Psychopharmacology

Volumn 28, Issue 5, 2014, Pages 403-439

  Baldwin, David S ^a,b   Anderson, Ian M ^c   Nutt, David J ^d   Allgulander, Christer ^e   Bandelow, Borwin ^f   Den Boer, Johan A ^g,h   Christmas, David M ⁱ   Davies, Simon ^j   Fineberg, Naomi ^k   Lidbetter, Nicky ^l   Malizia, Andrea ^m   McCrone, Paul ⁿ   Nabarro, Daniel ^o   O'Neill, Catherine ^l   Scott, Jan ^p   Van Der Wee, Nic ^q   Wittchen, Hans Ulrich ^r  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h PRA International Zuidlaren ^*  (Netherlands)

ⁱ CAMBRIDGESHIRE AND PETERBOROUGH NHS FOUNDATION TRUST   (United Kingdom)

^j UNIVERSITY OF TORONTO   (Canada)

^k UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^l Zion Community Centre   (United Kingdom)

^m NORTH BRISTOL NHS TRUST   (United Kingdom)

ⁿ KING'S COLLEGE LONDON   (United Kingdom)

^o OCD Action   (United Kingdom)

^p NEWCASTLE UNIVERSITY   (United Kingdom)

^q LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^r DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

more..

Author keywords

Anticonvulsants; antidepressants; antipsychotics; anxiety disorders; anxiolytics; benzodiazepines; cognitive behaviour therapy; evidence based guidelines; generalised anxiety disorder; obsessive compulsive disorder; panic disorder; post traumatic stress disorder; pregabalin; selective serotonin reuptake inhibitor; separation anxiety disorder; serotonin noradrenaline reuptake inhibitor; social anxiety disorder; specific phobia; treatment

Indexed keywords

AGOMELATINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; HYDROCORTISONE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PLACEBO; PREGABALIN; PROPRANOLOL; PSYCHOTROPIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADVERSE OUTCOME; ANXIETY DISORDER; ARTICLE; BREAST FEEDING; COGNITIVE THERAPY; COMORBIDITY; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEPRESSION; DRUG SAFETY; EVIDENCE BASED MEDICINE; GENERALIZED ANXIETY DISORDER; HEART DISEASE; HUMAN; LONG TERM CARE; MENTAL HEALTH SERVICE; NEUROLOGIC DISEASE; OBSESSIVE COMPULSIVE DISORDER; PANIC; PATIENT IDENTIFICATION; PATIENT REFERRAL; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; PREGNANT WOMAN; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHODYNAMIC PSYCHOTHERAPY; PSYCHOPHARMACOTHERAPY; SCREENING TEST; SECONDARY CARE CENTER; SELF HELP; SEPARATION ANXIETY; SOCIAL PHOBIA; TERTIARY CARE CENTER; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT RESPONSE; ANXIETY DISORDERS; DECISION MAKING; HEALTH CARE DELIVERY; OBSESSIVE-COMPULSIVE DISORDER; PROCEDURES; PSYCHOPHARMACOLOGY; STRESS DISORDERS, POST-TRAUMATIC;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DECISION MAKING; DELIVERY OF HEALTH CARE; EVIDENCE-BASED MEDICINE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOPHARMACOLOGY; STRESS DISORDERS, POST-TRAUMATIC;

EID: 84899839975     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114525674     Document Type: Article

References (486)

1. Abrantes AM, Strong DR, Cohn A, et al. Acute changes in obsessions and compulsions following moderate-intensity aerobic exercise among patients with obsessive-compulsive disorder. J Anxiety Disord. 2009 ; 23: 923-927
2. Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol. 2002 ; 22: 309-317
3. Aderka IM, Hofmann SG, Nickerson A, et al. Functional impairment in social anxiety disorder. J Anxiety Disord. 2012 ; 26: 393-400
4. Alamy S, Wei Z, Varia I, et al. Escitalopram in specific phobia: Results of a placebo-controlled pilot trial. J Psychopharmacol. 2008 ; 22: 157-161
5. Albus M, Scheibe G. Outcome of panic disorder with or without concomitant depression: A 2-year prospective follow-up study. Am J Psychiatry. 1993 ; 150: 1878-1880
6. Allgulander C, Dahl AA, Austin C, et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry. 2004a ; 161: 1642-1649
7. Allgulander C, Mangano R, Zhang J, et al. Efficacy of Venlafaxine ER in patients with social anxiety disorder: A double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol. 2004b ; 19: 387-396
8. Alper K, Schwartz KA, Kolts RL, et al. Seizure incidence in psychopharmacological clinical trials: An analysis of food and drug administration (FDA) summary basis of approval reports. Biol Psychiatry. 2007 ; 62: 345-354
9. Altamura AC, Serati M, Buoli M, et al. Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: A randomized, placebo-controlled study. Int Clin Psychopharmacol. 2011 ; 26: 201-205
10. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association ; 1994 :
11. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington DC: American Psychiatric Pub ; 2013 :
12. Amsterdam JD, Li Y, Soeller I, et al. A randomized, double-blind, placebo-controlled trial of oral matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J Clin Psychopharmacol. 2009 ; 29: 378-382
13. Anderson I, Ferrier I, Baldwin R, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008 ; 22: 343-396
14. Anderson IM, Nutt DJ, Deakin JFW. Evidence-based guidelines for treating depressive disorders with antidepressants, a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2000 ; 14: 3-20
15. Andersson E, Enander J, Andren P, et al. Internet-based cognitive behaviour therapy for obsessive-compulsive disorder: A randomized controlled trial. Psychol Med. 2012 ; 42: 2193-2203
16. Andersson G. Guided internet treatment for anxiety disorders. As effective as face-to-face therapies?. Stud Health Technol Inform. 2012 ; 181: 3-7
17. Andlin-Sobcki P, Wittchen HU. Cost of anxiety disorders in Europe. Eur J Neurol. 2005 ; 12: 39-44
18. Andrews G, Carter GL. What people say about their general practitioners' treatment of anxiety and depression. Med J Aust. 2001 ; 175: S48 - S51
19. Andrisano C, Chiesa A, Serretti A. Newer antidepressants and panic disorder: A meta-analysis. Int Clin Psychopharmacol. 2013 ; 28: 33-45
20. Angst J, Gamma A, Baldwin DS, et al. The generalized anxiety spectrum: Prevalence, onset, course and outcome. Eur Arch Psychiatry Clin Neurosci. 2009 ; 259: 37-45
21. Askari N, Moin M, Sanati M, et al. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2012 ; 26: 883-892
22. Baldwin D, Anderson I, Nutt D, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 ; 19: 567-596
23. Baldwin D, Woods R, Lawson R, et al. Efficacy of drug treatments for generalised anxiety disorder: Systematic review and meta-analysis. Brit Med J. 2011a ; 342: d1199
24. Baldwin DS, Kosky N. Off-label prescribing in psychiatric practice. Advances in Psychiatric Treatment. 2007 ; 13: 414-422
25. Baldwin DS, Talat B. Should benzodiazepines still have a role in treating patients with anxiety disorders?. Hum Psychopharmacol. 2012 ; 27: 237-238
26. Baldwin DS, Ajel K, Masdrakis VG, et al. Pregabalin for the treatment of generalized anxiety disorder: An update. Neuropsychiatr Dis Treat. 2013 ; 9: 883-892
27. Baldwin DS, Allgulander C, Altamura AC, et al. Manifesto for a European Anxiety Disorders Research Network. Eur Neuropsychopharmacol. 2010 ; 20: 426-432
28. Baldwin DS, Loft H, Florea I. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int Clin Psychopharmacol. 2012 ; 27: 197-207
29. Baldwin DS, Montgomery SA, Nil R, et al. Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol. 2007 ; 10: 73-84
30. Baldwin DS, Stein DJ, Dolberg OT, et al. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol. 2009 ; 24: 269-275
31. Baldwin DS, Waldman S, Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol. 2011b ; 14: 697-710
32. Ballenger JC. New treatments for panic. Eur Psychiatry. 1998 ; 13: 75s - 81s
33. Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998 ; 155: 36-42
34. Bandelow B, Seidler-Brandler U, Becker A, et al. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry. 2007a ; 8: 175-187
35. Bandelow B, Stein DI, Dolberg OT, et al. Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry. 2007b ; 40: 152-156
36. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessivecompulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry. 2008a ; 9: 248-312
37. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry. 2008b ; 9: 248-312
38. Barbui C, Cipriani A, Patel V, et al. Efficacy of antidepressants and benzodiazepines in minor depression: Systematic review and meta-analysis. Br J Psychiatry. 2011 ; 198: 11-16
39. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011 ; 25: 567-620
40. Bartzokis G, Lu PH, Turner J, et al. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry. 2005 ; 57: 474-479
41. Batelaan NM, de Graaf R, Penninx BWJH, et al. The 2-year prognosis of panic episodes in the general population. Psychol Med. 2010a ; 40: 147-157
42. Batelaan NM, de Graaf R, Spijker J, et al. The course of panic attacks in individuals with panic disorder and subthreshold panic disorder: A population-based study. J Affect Disord. 2010b ; 121: 30-38
43. Batelaan NM, Van Balkom AJLM, Stein DJ. Evidence-based pharmacotherapy of panic disorder: An update. Int J Neuropsychopharmacol. 2012 ; 15: 403-415
44. Beard C, Moitra E, Weisberg RB, et al. Characteristics and predictors of social phobia course in a longitudinal study of primary-care patients. Depress Anxiety. 2010 ; 27: 839-845
45. Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry. 2007 ; 40: 163-168
46. Benjamin J, Ben-Zion IZ, Karbofsky E, et al. Double-blind placebo-controlled pilot study of paroxetine for specific phobia. Psychopharmacology (Berl). 2000 ; 149: 194-196
47. Bereza BG, Machado M, Einarson TR. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder. Clin Ther. 2009 ; 31: 1279-1308
48. Bergamaschi MM, Costa Queiroz RH, Nisihara Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011 ; 36: 1219-1226
49. Berlin HA, Koran LM, Jenike MA, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011 ; 72: 716-721
50. Bertani A, Perna G, Migliarese G, et al. Comparison of the treatment with paroxetine and reboxetine in panic disorder: A randomized, single-blind study. Pharmacopsychiatry. 2004 ; 37: 206-210
51. Beyenburg S, Mitchell AJ, Schmidt D, et al. Anxiety in patients with epilepsy: Systematic review and suggestions for clinical management. Epilepsy Behav. 2005 ; 7: 161-171
52. Bielski RJ, Bose A, Chang C-C. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry. 2005 ; 17: 65-69
53. Bismuth-Evenzal Y, Gonopolsky Y, Gurwitz D, et al. Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. J Affect Disord. 2012 ; 136: 99-103
54. Bisson J, Andrew M. Psychological treatment of post-traumatic stress disorder. Cochrane Database Syst Rev. 2007 ; 3: CD003388
55. Blanco C, Bragdon LB, Schneier FR, et al. The evidence-based pharmacotherapy of social anxiety disorder. Int J Neuropsychopharmacol. 2013 ; 16: 235-249
56. Blanco C, Heimberg RG, Schneier FR, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry. 2010 ; 67: 286-295
57. Bloch MH, McGuire J, Landeros-Weisenberger A, et al. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry. 2010 ; 15: 850-855
58. Blomstedt P, Sjöberg R, Hansson M, et al. Deep brain stimulation in the treatment of obsessive-compulsive disorder. World Neurosurg. 2013 ; 80: e245 - e253
59. Bögels SM, Knappe S, Clark LA. Adult separation anxiety disorder in DSM-5. Clin Psychol Rev. 2013 ; 33: 663-674
60. Bower P, Richards D, Lovell K. The clinical and cost-effectiveness of self-help treatments for anxiety and depressive disorders in primary care: A systematic review. Br J Gen Pract. 2001 ; 51: 838-845
61. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: A double-blind, placebo-controlled study. J Clin Psychiatry. 2005 ; 66: 1321-1325
62. Broocks A, Bandelow B, Pekrun G, et al. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry. 1998 ; 155: 603-609
63. Brown C, Schulberg HC, Madonia MJ, et al. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry. 1996 ; 153: 1293-1300
64. Brown JSL, Boardman J, Whittinger N, et al. Can a self-referral system help improve access to psychological treatments?. Br J Gen Pract. 2010 ; 60: 365-371
65. Brown TA, Antony MM, Barlow DH. Diagnostic comorbidity in panic disorder: Effect on treatment outcome and course of comorbid diagnoses following treatment. J Consult Clin Psychol. 1995 ; 63: 408-418
66. Bruce SE, Yonkers KA, Otto MW, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: A 12-year prospective study. Am J Psychiatry. 2005 ; 162: 1179-1187
67. Bruno A, Mico U, Pandolfo G, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled study. J Psychopharmacol. 2012 ; 26: 1456-1462
68. Buckley PF, Miller BJ, Lehrer DS, et al. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009 ; 35: 383-402
69. Buckner JD, Schmidt NB, Lang AR, et al. Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. J Psychiatr Res. 2008 ; 42: 230-239
70. Burns A. Clinical practice with anti-dementia drugs: A consensus statement from British Association for Psychopharmacology. J Psychopharmacol. 2006 ; 20: 732-755
71. Burstein M, Ameli-Grillo L, Merikangas KR. Shyness versus social phobia in US youth. Pediatrics. 2011 ; 128: 917-925
72. Burstein M, Georgiades K, He J-P, et al. Specific phobia among U.S. adolescents: Phenomenology and typology. Depress Anxiety. 2012 ; 29: 1072-1082
73. Burton C, McGorm K, Weller D, et al. Depression and anxiety in patients repeatedly referred to secondary care with medically unexplained symptoms: A case-control study. Psychol Med. 2011 ; 41: 555-563
74. Buse D, Silberstein S, Manack A, et al. Psychiatric comorbidities of episodic and chronic migraine. J Neurol. 2013 ;:
75. Buszewicz MJ, Chew-Graham C. Improving the detection and management of anxiety disorders in primary care. Br J Gen Pract. 2011 ; 61: 489-490
76. Calleo J, Stanley MA, Greisinger A, et al. Generalized anxiety disorder in older medical patients: Diagnostic recognition, mental health management and service utilization. J Clin Psychol Med Settings. 2009 ; 16: 178-185
77. Campbell Burton C, Murray J, Holmes J, et al. Frequency of anxiety after stroke: A systematic review and meta-analysis of observational studies. Int J Stroke. 2013 ; 8: 545-559
78. Campbell Burton CA, Holmes J, Murray J, et al. Interventions for treating anxiety after stroke. Cochrane Database Syst Rev (Online). 2011 ;: CD008860
79. Canton J, Scott KM, Glue P. Optimal treatment of social phobia: Systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2012 ; 8: 203-215
80. Cape J, McCulloch Y. Patients' reasons for not presenting emotional problems in general practice consultations. Br J Gen Pract. 1999 ; 49: 875-879
81. Cape J, Whittington C, Buszewicz M, et al. Brief psychological therapies for anxiety and depression in primary care: Meta-analysis and meta-regression. BMC Medicine. 2010 ; 8: 38
82. Carey P, Suliman S, Ganesan K, et al. Olanzapine monotherapy in postraumatic stress disorder: Efficacy in a randomized, double-blind, placebo-controlled study. Hum Psychopharmacol. 2012 ; 27: 386-391
83. Castle D. Anxiety and substance use: Layers of complexity. Expert Rev Neurother. 2008 ; 8: 493-501
84. Chen K, Berger C, Manheimer E, et al. Meditative therapies for reducing anxiety: A systematic erview and meta-analysis of randomised controlled trials. Depress Anxiety. 2012 ; 29: 545-562
85. Chessick CA, Allen HA, Thase ME, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 2006 ; 19: CD006115
86. Christensen KS, Toft T, Frostholm L, et al. Screening for common mental disorders: Who will benefit? Results from a randomised clinical trial. Fam Pract. 2005 ; 22: 428-434
87. Chung MY, Min KH, Jun YJ, et al. Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: A randomized open label trial. Hum Psychopharmacol. 2004 ; 19: 489-494
88. Cipriani A, Koesters M, Furukawa TA, et al. Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev (Online). 2012 ; 10: CD006533
89. Clark DM. Implementing NICE guidelines for the psychological treatment of depression and anxiety disorders: The IAPT experience. Int Rev Psychiatry. 2011 ; 23: 318-327
90. Clark DM, Salkovskis PM, Hackmann A, et al. Two psychological treatments for hypochondriasis: A randomized controlled trial. Br J Psychiatry. 1998 ; 173: 218-225
91. Coles ME, Pinto A, Mancebo MC, et al. OCD with comorbid OCPD: A subtype of OCD?. J Psychiatr Res. 2008 ; 42: 289-296
92. Comino E, Harris E, Silove D, et al. Prevalence, detection and management of anxiety and depressive symptoms in unemployed patients attending general practitioners. Aust N Z J Psychiatry. 2000 ; 34: 107-113
93. Committee on Safety of Medicines (2004) Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants. Available at www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/ con019472.pdf (accessed 27 February 2013).
94. Connor KM, Davidson JRT, Weisler RH, et al. Tiagabine for posttraumatic stress disorder: Effects of open-label and double-blind discontinuation treatment. Psychopharmacology (Berl). 2006 ; 184: 21-25
95. Copeland WE, Angold A, Shanahan L, et al. Longitudinal patterns of anxiety from childhood to adulthood: The great smoky mountains study. J Am Acad Child Adolesc Psychiatry. 2014 ; 53: 21-33
96. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial. Biol Psychiatry. 2005 ; 58: 424-428
97. Cottraux J, Mollard E, Bouvard M, et al. A controlled-study of fluvoxamine and exposure in obsessive-compulsive disorder. International J Clin Psychopharmacol. 1990 ; 5: 17-30
98. Cournoyer J. Reponse rapide a l'addition du carbonate de lithium d'un trouble: Panique resistant aux antidepresseurs tricycliques [Rapid response of a disorder to the addition of lithium carbonate: Panic resistant to tricyclic antidepressants]. Can J Psychiatry. 1986 ; 31: 335-338
99. Cowley DS, Flick SN, RoyByrne PP. Long-term course and outcome in panic disorder: A naturalistic follow-up study. Anxiety. 1996 ; 2: 13-21
100. Craske MG, Edlund MJ, Sullivan G, et al. Perceived unmet need for mental health treatment and barriers to care among patients with panic disorder. Psychiatr Serv. 2005 ; 56: 988-994
101. Crippa JA, Zuardi AW, Martin-Santos R, et al. Cannabis and anxiety: A critical review of the evidence. Hum Psychopharmacol. 2009 ; 24: 515-523
102. Crits-Christoph P, Newman MG, Rickels K, et al. Combined medication and cognitive therapy for generalized anxiety disorder. J Anxiety Disord. 2011 ; 25: 1087-1094
103. Cuijpers P, Donker T, van Straten A, et al. Is guided self-help as effective as face-to-face psychotherapy for depression and anxiety disorders? A systematic review and meta-analysis of comparative outcome studies. Psychol Med. 2010 ; 40: 1943-1957
104. Dannon PN, Iancu I, Lowengrub K, et al. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clin Neuropharmacol. 2007 ; 30: 326-334
105. Davidson J, Baldwin D, Stein DJ, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release - a 6-month randomized controlled trial. Arch Gen Psychiatry. 2006a ; 63: 1158-1165
106. Davidson J, Rothbaum BO, Tucker P, et al. Venlafaxine extended release in posttraumatic stress disorder - a sertraline- and placebo-controlled study. J Clin Psychopharmacol. 2006b ; 26: 259-267
107. Davidson JRT, Connor KM, Hertzberg MA, et al. Maintenance therapy with fluoxetine in posttraumatic stress disorder - a placebo-controlled discontinuation study. J Clin Psychopharmacol. 2005 ; 25: 166-169
108. Davidson JRT, Crawford C, Ives JA, et al. Homeopathic treatments in psychiatry: A systematic review of randomized placebo-controlled studies. J Clin Psychiatry. 2011 ; 72: 795-805
109. Davies SJ, Lowry CA, Nutt DJ. Panic and hypertension: Brothers in arms through 5-HT?. J Psychopharmacol. 2007 ; 21: 563-566
110. De Kleine RA, Hendriks G-J, Kusters WJC, et al. A randomized placebo-controlled trial of d-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psychiatry. 2012 ; 71: 962-968
111. De Koning PP, Figee M, van den Munckhof P, et al. Current status of deep brain stimulation for obsessive-compulsive disorder: A clinical review of different targets. Curr Psychiatry Rep. 2011 ; 13: 274-282
112. De Menezes GB, Freire Coutinho ES, Fontenelle LF, et al. Second-generation antidepressants in social anxiety disorder: Meta-analysis of controlled clinical trials. Psychopharmacology (Berl). 2011 ; 215: 1-11
113. Deacon B, Lickel J, Abramowitz JS. Medical utilization across the anxiety disorders. J Anxiety Disord. 2008 ; 22: 344-350
114. Dell'Osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry. 2012 ; 28: 7-20
115. Den Boer JA, Westenberg HG. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol. 1988 ; 3: 59-74
116. Denys D, van der Wee N, van Megen H, et al. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol. 2003 ; 23: 568-575
117. Depping AM, Komossa K, Kissling W, et al. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010 ; 12: CD008120
118. Dieleman GC, Ferdinand RF. Pharmacotherapy for social phobia, generalised anxiety disorder and separation anxiety disorder in children and adolescents: An overview. Tijdschr Psychiatr. 2008 ; 50: 43-53
119. Dingemanse J, Wood N, Guentert T, et al. Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects. Psychopharmacology (Berl). 1998 ; 140: 164-172
120. Dold M, Aigner M, Lanzenberger R, et al. Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder - a meta-analysis of double-blind, randomised, placebo-controlled trials. Fortschr Neurol Psychiatr. 2011 ; 79: 453-466
121. Donker T, Comijs H, Cuijpers P, et al. The validity of the Dutch K10 and extended K10 screening scales for depressive and anxiety disorders. Psychiatry Res. 2010 ; 176: 45-50
122. Donovan MR, Glue P, Kolluri S, et al. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis. J Affect Disord. 2010 ; 123: 9-16
123. Dubois O, Salamon R, Germain C, et al. Balneotherapy versus paroxetine in the treatment of generalized anxiety disorder. Complement Ther Med. 2010 ; 18: 1-7
124. Durham R, Fisher P, Trevling L, et al. One year follow-up of cognitive therapy, analytic psychotherapy and anxiety managemment training for generalized anxiety disorder: Symptom change, medication usage and attitudes to treatment. Behav Cogn Psychother. 1999 ; 27: 19-35
125. Durham RC, Chambers JA, Power KG, et al. Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland. Health Technol Assess (Rockv). 2005 ; 9: 1-174
126. Ehrenreich JT, Santucci LC, Weiner CL. Separation anxiety disorder in youth: Phenomenology, assessment, and treatment. Psicol Conductual. 2008 ; 16: 389-412
127. Eisen JL, Pinto A, Mancebo MC, et al. A 2-year prospective follow-up study of the course of obsessive-compulsive disorder. J Clin Psychiatry. 2010 ; 71: 1033-1039
128. Emmanuel J, Simmonds S, Tyrer P. Systematic review of the outcome of anxiety and depressive disorders. Br J Psychiatry Suppl. 1998 ; 34: 35-41
129. Erwin BA, Heimberg RG, Juster H, et al. Comorbid anxiety and mood disorders among persons with social anxiety disorder. Behav Res Ther. 2002 ; 40: 19-35
130. Evans RW, Tepper SJ, Shapiro RE, et al. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010 ; 50: 1089-1099
131. Fallon BA, Liebowitz MR, Campeas R, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine - A placebo-controlled study. Arch Gen Psychiatry. 1998 ; 55: 918-924
132. Fallon BA, Petkova E, Skritskaya N, et al. A double-masked, placebo-controlled study of fluoxetine for hypochondriasis. J Clin Pharmacol. 2008 ; 28: 638-645
133. Farrell L, Waters A, Milliner E, et al. Comorbidity and treatment response in pediatric obsessive-compulsive disorder: A pilot study of group cognitive-behavioral treatment. Psychiatry Res. 2012 ; 199: 115-123
134. Fassaert T, Nielen M, Verheij R, et al. Quality of care for anxiety and depression in different ethnic groups by family practitioners in urban areas in the Netherlands. Gen Hosp Psychiatry. 2010 ; 32: 368-376
135. Fehm L, Pelissolo A, Furmark T, et al. Size and burden of social phobia in Europe. Eur Neuropsychopharmacol. 2005 ; 15: 453-462
136. Fibbe LA, Cath DC, van den Heuvel OA, et al. Relationship between movement disorders and obsessive-compulsive disorder: Beyond the obsessive-compulsive-tic phenotype. A systematic review. J Neurol Neurosurg Psychiatry. 2012 ; 83: 646-654
137. Fineberg N, Hengartner M, Bergbaum C, et al. A prospective population-based cohort study of the prevalence, incidence and impact of obsessive-compulsive symptomatology. Int J Psychiatry Clin Pract. 2013 ; 17: 170-178
138. Fineberg NA, Brown A, Reghunandanan S, et al. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2012 ; 15: 1173-1191
139. Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2005 ; 8: 107-129
140. Fineberg NA, Tonnoir B, Lemming O, et al. Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2007 ; 17: 430-439
141. Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005 ; 162: 151-161
142. Fontenelle LF, Mendlowicz MV, Marques C, et al. Trans-cultural aspects of obsessive-compulsive disorder: A description of a Brazilian sample and a systematic review of international clinical studies. J Psychiatr Res. 2004 ; 38: 403-411
143. Francois C, Montgomery SA, Despiegel N, et al. Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder. Int J Clin Pract. 2008 ; 62: 1693-1702
144. Franklin ME, Sapyta J, Freeman JB, et al. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: The Pediatric OCD Treatment Study II (POTS II) randomized controlled trial. JAMA. 2011 ; 306: 1224-1232
145. Frommberger U, Stieglitz RD, Nyberg E, et al. Comparison between paroxetine and behaviour therapy in patients with posttraumatic stress disorder (PTSD): A pilot study. Int J Psychiatry Clin Pract. 2004 ; 8: 19-23
146. Furukawa TA, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database Syst Rev. 2007 ;:
147. Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder an updated meta-analysis. Ann Intern Med. 2011 ; 155: 772-785
148. Garyfallos G, Katsigiannopoulos K, Adamopoulou A, et al. Comorbidity of obsessive-compulsive disorder with obsessive-compulsive personality disorder: Does it imply a specific subtype of obsessive-compulsive disorder?. Psychiatry Res. 2010 ; 177: 156-160
149. Gaudiano BA, Miller IW. Anxiety disorder comobidity in bipolar I disorder: Relationship to depression severity and treatment outcome. Depress Anxiety. 2005 ; 21: 71-77
150. Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioural and pharmacological treatment of social phobia - a controlled study. Arch Gen Psychiatry. 1991 ; 48: 938-945
151. Gelpin E, Bonne O, Peri T, et al. Treatment of recent trauma survivors with benzodiazepines: A prospective study. J Clin Psychiatry. 1996 ; 57: 390-394
152. Gentile S. Efficacy of antidepressant medications in children and adolescents with obsessive-compulsive disorder a systematic appraisal. J Clin Psychopharmacol. 2011 ; 31: 625-632
153. George DT, Ladenheim JA, Nutt DJ. Effect of pregnancy on panic attacks. Am J Psychiatry. 1987 ; 144: 1078-1079
154. Gillies D, Taylor F, Gray C, et al. Psychological therapies for the treatment of post-traumatic stress disorder in children and adolescents. Cochrane Database Syst Rev. 2012 12 ; 12: CD006726
155. Goncalves DC, Byrne GJ. Interventions for generalized anxiety disorder in older adults: Systematic review and meta-analysis. J Anxiety Disord. 2012 ; 26: 1-11
156. Goodwin G. Evidence-based guidelines for treating bipolar disorder: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2003 ; 17: 149-173
157. Goodwin G, Anderson I, Arango C, et al. ECNP consensus meeting. Bipolar depression. Nice, March 2007. Eur Neuropsychopharmacol. 2008 ; 18: 535-549
158. Goodwin GM. What outcomes, what interventions - the methodology. Eur Neuropsychopharmacol. 2005 ; 15: S333 - S334
159. Goodwin GM, Emsley R, Rembry S, et al. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: A 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009 ; 70: 1128-1137
160. Goodwin RD, Faravelli C, Rosi S, et al. The epidemiology of panic disorder and agoraphobia in Europe. Eur Neuropsychopharmacol. 2005 ; 15: 435-443
161. Gospodarevskaya E, Segal L. Cost-utility analysis of different treatments for post-traumatic stress disorder in sexually abused children. Child Adolesc Psychiatry Ment Health. 2012 ; 6: 15
162. Gould RL, Coulson MC, Howard RJ. Efficacy of cognitive behavioral therapy for anxiety disorders in older people: A meta-analysis and meta-regression of randomized controlled trials. J Am Geriatr Soc. 2012 ; 60: 218-229
163. Greenberg BD, Suzanne SLR, Haber SN. Invasive circuitry-based neurotherapeutics: Stereotactic ablation and deep brain stimulation for OCD. Neuropsychopharmacology. 2010 ; 35: 317-336
164. Greenberg WM, Benedict MM, Doerfer J, et al. Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. J Psychiatr Res. 2009 ; 43: 664-670
165. Greist JH, Jefferson JW, Kobak KA, et al. A 1-year double-blind placebo-controlled fixed-dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995 ; 10: 57-65
166. Griffiths KM, Farrer L, Christensen H. The efficacy of internet interventions for depression and anxiety disorders: A review of randomised controlled trials. Med J Aust. 2010 ; 192: S4 - S11
167. Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev. 2010 ; 8: CD006815
168. Guastella AJ, Dadds MR, Lovibond PF, et al. A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. J Psychiatr Res. 2007 ; 41: 466-471
169. Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008 ; 63: 544-549
170. Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 ; 21: 718-779
171. Hamner MB, Faldowski RA, Ulmer HG, et al. Adjunctive risperidone treatment in post-traumatic stress disorder: A preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol. 2003 ; 18: 1-8
172. Harrison CL, Ferrier N, Young AH. Tolerability of high-dose venlafaxine in depressed patients. J Psychopharmacol. 2004 ; 18: 200-204
173. Haynes R, Devereaux P, Guyatt G. Physicians' and patients'choices in evidence based practice. Brit Med J. 2002 1350 ; 324 :
174. Hedman E, Andersson E, Ljotsson B, et al. Cost-effectiveness of Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: Results from a randomized controlled trial. Behav Res Ther. 2011a ; 49: 729-736
175. Hedman E, Andersson G, Andersson E, et al. Internet-based cognitive-behavioural therapy for severe health anxiety: Randomised controlled trial. Br J Psychiatry. 2011b ; 198: 230-236
176. Hedman E, Furmark T, Carlbring P, et al. A 5-year follow-up of internet-based cognitive behavior therapy for social anxiety disorder. J Med Internet Res. 2011c ; 13 (2). e39
177. Heiser NA, Turner SM, Beidel DC, et al. Differentiating social phobia from shyness. J Anxiety Disord. 2009 ; 23: 469-476
178. Heldt E, Manfro GG, Kipper L, et al. Treating medication-resistant panic disorder: Predictors and outcome of cognitive-behavior therapy in a Brazilian public hospital. Psychother Psychosom. 2003 ; 72: 43-48
179. Henry C, Van den Bulke D, Bellivier F, et al. Anxiety disorders in 318 bipolar patients: Prevalence and impact on illness severity and response to mood stabilizer. J Clin Psychiatry. 2003 ; 64: 331-335
180. Herrera-Arellano A, Jimenez-Ferrer E, Zamilpa A, et al. Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam. Planta Med. 2007 ; 73: 713-717
181. Herring MP, Jacob ML, Suveg C, et al. Feasibility of exercise training for the short-term treatment of generalized anxiety disorder: A randomized controlled trial. Psychother Psychosom. 2012 ; 81: 21-28
182. Herring MP, O'Connor PJ, Dishman RK. The effect of exercise training on anxiety symptoms among patients a systematic review. Arch Intern Med. 2010 ; 170: 321-331
183. Hetrick SE, McKenzie JE, Cox GR, et al. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2012 ; 11: CD004851
184. Hetrick SE, Purcell R, Garner B, et al. Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2010 ; 7: CD007316
185. Heuzenroeder L, Donnelly M, Haby MM, et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust N Z J Psychiatry. 2004 ; 38: 602-612
186. Hidalgo RB, Tupler LA, Davidson JRT. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol. 2007 ; 21: 864-872
187. Hirschmann S, Dannon PN, Iancu I, et al. Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2000 ; 20: 556-559
188. Hofmann SG, Meuret AE, Smits JAJ, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006 ; 63: 298-304
189. Hofmann SG, Smits JAJ. Cognitive-behavioral therapy for adult anxiety disorders: A meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry. 2008 ; 69: 621-632
190. Hohagen F, Winkelmann G, Rasche-Rauchle H, et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo - results of a multicentre study. Br J Psychiatry. 1998 ; 173: 71-78
191. Holsboer-Trachsler E, Prieto R. Effects of pregabalin on sleep in generalized anxiety disorder. Int J Neuropsychopharmacol. 2013 ; 16: 925-936
192. Holtkamp K, Herpertz-Dahlmann B. SSRI and SNRI treatment in children and adolescents. Current views of the benefits and risks. Nervenarzt. 2008 ; 79: 1237-1238
193. Hosenbocus S, Chahal R. SSRIs and SNRIs: A review of the discontinuation syndrome in children and adolescents. J Can Acad Child Adolesc Psychiatry. 2011 ; 20: 60-67
194. Hovland A, Nordhus I, Sjøbø T, et al. Comparing physical exercise in groups to group cognitive behaviour therapy for the treatment of panic disorder in a randomized controlled trial. Behav Cogn Psychother. 2012 ; 5: 1-25
195. Hyde J, Evans J, Sharp D, et al. Deciding who gets treatment for depression and anxiety: A study of consecutive GP attenders. Br J Gen Pract. 2005 ; 55: 846-853
196. Ipser JC, Stein DJ. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). Int J Neuropsychopharmacol. 2012 ; 15: 825-840
197. Ipser JC, Stein DJ, Hawkridge S, et al. Pharmacotherapy for anxiety disorders in children and adolescents (Review). Cochrane Database Syst Rev. 2009 ; 3: CD005170
198. Iskedjian M, Walker JH, Bereza BG, et al. Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada. Curr Med Res Opin. 2008 ; 24: 1539-1548
199. Issakidis C, Sanderson K, Corry J, et al. Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders. Psychol Med. 2004 ; 34: 19-35
200. James A, Soler A, Weatherall R. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev. 2005 ; 4: CD004690
201. Jazaieri H, Goldin PR, Werner K, et al. A randomized trial of mindfulnessbased stress reduction versus aerobic exercise for social anxiety disorder. J Clin Psychol. 2012 ; 68: 715-731
202. Joesch JM, Sherbourne CD, Sullivan G, et al. Incremental benefits and cost of coordinated anxiety learning and management for anxiety treatment in primary care. Psychol Med. 2012 ; 42: 1937-1948
203. Johnson MR, Gold PB, Siemion L, et al. Panic disorder in primary care: Patients' attributions of illness causes and willingness to accept psychiatric treatment. Int J Psychiatry Med. 2000 ; 30: 367-384
204. British National Formulary (BNF) 65. London: BMJ Publishing Group Ltd and Royal Pharmaceutical ; 2012 :
205. Jones PB. Adult mental health disorders and their age at onset. Br J Psychiatry. 2013 ; 202: s5 - s10
206. Jonsson H, Hougaard E. Group cognitive behavioural therapy for obsessive-compulsive disorder: A systematic review and meta-analysis. Acta Psychiatr Scand. 2009 ; 119: 98-106
207. Jorgensen TR, Stein DJ, Despiegel N, et al. Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom. Ann Pharmacother. 2006 ; 40: 1752-1758
208. Kadam UT, Croft P, McLeod J, et al. A qualitative study of patients' views on anxiety and depression. Br J Gen Pract. 2001 ; 51: 375-380
209. Kampman M, Keijsers GPJ, Hoogduin CAL, et al. A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. J Clin Psychiatry. 2002 ; 63: 772-777
210. Katz RJ, Deveaughgeiss J, Landau P. Clomipramine in obsessive-compulsive disorder. Biol Psychiatry. 1990 ; 28: 401-414
211. Katzman MA, Brawman-Mintzer O, Reyes EB, et al. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: A long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011 ; 26: 11-24
212. Katzman MA, Vermani M, Gerbarg PL, et al. A multicomponent yoga-based, breath intervention program as an adjunctive treatment in patients suffering from generalized anxiety disorder with or without comorbidities. Int J Yoga. 2012 ; 5: 57-65
213. Kempe P, van Oppen P, de Haan E, et al. Predictors of course in obsessive-compulsive disorder: Logistic regression versus Cox regression for recurrent events. Acta Psychiatr Scand. 2007 ; 116: 201-210
214. Kessler D, Bennewith O, Lewis G, et al. Detection of depression and anxiety in primary care: Follow up study. Brit Med J. 2002 ; 325: 1016-1017
215. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions' of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005 ; 62: 593-602
216. Kessler RC, Gruber M, Hettema JM, et al. Co-morbid major depression and generalized anxiety disorders in the National Comborbity Survey follow-up. Psychol Med. 2008 ; 38: 365-374
217. Kessler RC, Petukhova M, Sampson NA, et al. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012 ; 21: 169-184
218. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995 ; 52: 1048-1060
219. Khan A, Atkinson S, Mezhebovsky I, et al. Extended release quetiapine fumarate (quetiapine XR) as adjunct therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: A randomized. double-blind study. Ann Clin Psychiatry. 2013 ; 25: E7-22
220. Kircanski K, Peris TS, Piacentini JC. Cognitive-behavioral therapy for obsessive-compulsive disorder in children and adolescents. Child and Adolescent Psychiatr Clin North Am. 2011 ; 20: 239-254
221. Klein B, Austin D, Pier C, et al. Internet-based treatment for panic disorder: Does frequency of therapist contact make a difference?. Cogn Behav Ther. 2009 ; 38: 100-113
222. Konnopka A, Leichsenring F, Leibing E, et al. Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: A systematic review. J Affect Disord. 2009 ; 114: 14-31
223. Koran LM, Aboujaoude E, Bullock KD, et al. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2005 ; 66: 353-359
224. Koran LM, Aboujaoude E, Gamel NN. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2009 ; 70: 1530-1535
225. Koszycki D, Raab K, Aldosary F, et al. A multifaith spiritually based intervention for generalized anxiety disorder: A pilot randomized trial. J Clin Psychol. 2010 ; 66: 430-441
226. Koszycki D, Taljaard M, Segal Z, et al. A randomized trial of sertraline, self-administered cognitive behavior therapy, and their combination for panic disorder. Psychol Med. 2011 ; 41: 373-383
227. Kowalik J, Weller J, Venter J, et al. Cognitive behavioral therapy for the treatment of pediatric posttraumatic stress disorder: A review and meta-analysis. J Behav Ther Exp Psychiatry. 2011 ; 42: 405-413
228. Kozak AT, Spates CR, McChargue DE, et al. Naltrexone renders one-session exposure therapy less effective: A controlled pilot study. J Anxiety Disord. 2007 ; 21: 142-152
229. Krisanaprakornit T, Krisanaprakornit W, Piyavhatkul N, et al. Meditation therapy for anxiety disorders. Cochrane Database Systemic Reviews. 2006 ; 25: CD004998
230. Kruger MB, Dahl AA. The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. Eur Arch Psychiatry Clin Neurosci. 1999 ; 249: S19 - S24
231. Krysinska K, Lester D. Post-traumatic stress disorder and suicide risk: A systematic review. Arch Suicide Res. 2010 ; 14: 1-23
232. Krystal JH, Rosenheck RA, Cramer JA, et al. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: A randomized trial. JAMA. 2011 ; 306: 493-502
233. Kushner MG, Kim SW, Donahue C, et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry. 2007 ; 62: 835-838
234. Lader M, Stender K, Burger V, et al. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety. 2004 ; 19: 241-248
235. Lagomasino IT, Stockdale SE, Miranda J. Racial-ethnic composition of provider practices and disparities in treatment of depression and anxiety, 2003-2007. Psychiatr Serv. 2011 ; 62: 1019-1025
236. Lakhan SE, Vieira KF. Nutritional and herbal supplements for anxiety and anxiety-related disorders: Systematic review. Nutr J. 2010 ; 9: 42
237. Lalonde CD, Van Lieshout RJ. Treating generalized anxiety disorder with second generation antipsychotics a systematic review and meta-analysis. J Clin Psychopharmacol. 2011 ; 31: 326-333
238. Lambert RA, Lorgelly P, Harvey I, et al. Cost-effectiveness analysis of an occupational therapy-led lifestyle approach and routine general practitioner's care for panic disorder. Soc Psychiatry Psychiatr Epidemiol. 2010 ; 45: 741-750
239. Lane R, Baldwin DS. Selective serotonin reuptake inhibitor-induced serotonin syndrome: A review. J Clin Psychopharmacol. 1997 ; 17: 209-221
240. Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand. 1997 ; 95: 153-160
241. Leichsenring F. Are psychodynamic and psychoanalytic therapies effective? A review of empirical data. Int J Psychoanal. 2005 ; 86: 841-868
242. Leichsenring F, Salzer S, Jaeger U, et al. Short-term psychodynamic psychotherapy and cognitive-behavioral therapy in generalized anxiety disorder: A randomized, controlled trial. Am J Psychiatry. 2009 ; 166: 875-881
243. Lepola UM, Wade AG, Leinonen EV, et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry. 1998 ; 59: 528-534
244. Lewis AJ, Dennerstein M, Gibbs PM. Short-term psychodynamic psychotherapy: Review of recent process and outcome studies. Aust N Z J Psychiatry. 2008 ; 42: 445-455
245. Lewis C, Pearce J, Bisson JI. Efficacy, cost-effectiveness and acceptability of self-help interventions for anxiety disorders: Systematic review. Br J Psychiatry. 2012 ; 200: 15-21
246. Leydon GM, Dowrick CF, McBride AS, et al. Questionnaire severity measures for depression: A threat to the doctor-patient relationship?. Br J Gen Pract. 2011 ; 61: 117-123
247. Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol. 2005 ; 15: 445-452
248. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo, and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005 ; 62: 190-198
249. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia - a placebo-controlled comparison. Arch Gen Psychiatry. 1992 ; 49: 290-300
250. Liebschutz J, Saitz R, Brower V, et al. PTSD in urban primary care: High prevalence and low physician recognition. J Gen Intern Med. 2007 ; 22: 719-726
251. Lingford-Hughes AR, Welch S, Nutt DJ, et al. Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2004 ; 18: 293-335
252. Lingford-Hughes AR, Welch S, Peters L, et al. Evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: Recommendations from BAP. J Psychopharmacol. 2012 ; 26: 899-952
253. Litz BT, Salters-Pedneault K, Steenkamp MM, et al. A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res. 2012 ; 46: 1184-1190
254. Lochner C, Serebro P, van der Merwe L, et al. Comorbid obsessive-compulsive personality disorder in obsessive-compulsive disorder (OCD): A marker of severity. Prog Neuropsychopharmacol Biol Psychiatry. 2011 ; 35: 1087-1092
255. Loewe B, Kroenke K, Spitzer RL, et al. Trauma exposure and posttraumatic stress disorder in primary care patients: Cross-sectional criterion standard study. J Clin Psychiatry. 2011 ; 72: 304-312
256. Lohoff FW, Etemad B, Mandos LA, et al. Ziprasidone treatment of refractory generalized anxiety disorder a placebo-controlled, double-blind study. J Clin Psychopharmacol. 2010 ; 30: 185-189
257. Londborg PD, Hegel MT, Goldstein S, et al. Sertraline treatment of posttraumatic stress disorder: Results of 24 weeks of open-label continuation treatment. J Clin Psychiatry. 2001 ; 62: 325-331
258. Lopez-Vilchez I, Diaz-Ricart M, White JG, et al. Serotonin enhances platelet procoagulant properties and their activation induced during platelet tissue factor uptake. Cardiovasc Res. 2009 ; 84: 309-316
259. Lydiard RB, Rickels K, Herman B, et al. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol. 2010 ; 13: 229-241
260. McAllister-Williams RH, Baldwin DS, Haddad PM, et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 ; 25: 95-102
261. McCrone P. IAPT is probably not cost-effective. Br J Psychiatry. 2013 ; 202: 383
262. McCrone P, Marks IM, Mataix-Cols D, et al. Computer-aided self-exposure therapy for phobia/panic disorder: A pilot economic evaluation. Cogn Behav Ther. 2009 ; 38: 91-99
263. McHugh RK, Otto MW, Barlow DH, et al. Cost-efficacy of individual and combined treatments for panic disorder. J Clin Psychiatry. 2007 ; 68: 1038-1044
264. McHugh RK, Smits JAJ, Otto MW. Empirically supported treatments for panic disorder. Psychiatr Clin North Am. 2009 ; 32: 593-610
265. McIntyre RS, Panjwani ZD, Nguyen HT, et al. The hepatic safety profile of duloxetine: A review. Expert Opin Drug Metab Toxicol. 2008 ; 4: 281-285
266. Mackenzie CS, Reynolds K, Cairney J, et al. Disorder-specific mental health service use for mood and anxiety disorders: Associations with age, sex, and psychiatric comorbidity. Depress Anxiety. 2012 ; 29: 234-242
267. McManus F, Surawy C, Muse K, et al. A randomized clinical trial of mindfulness-based cognitive therapy versus unrestricted services for health anxiety (hypochondriasis). J Consult Clin Psychol. 2012 ; 80: 817-828
268. Manzoni G, Pagnini F, Castelnuovo G, et al. Relaxation therapy for anxiety: A ten-years systematic review with meta-analysis. BMC Psychiatry. 2008 ; 8: 41
269. March JS, Foa E, Gammon P, et al. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder - The Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA. 2004 ; 292: 1969-1976
270. Marks IM, Lelliott P, Basoglu M, et al. Clomipramine, self-exposure and therapist-aided exposure for obsessive compulsive rituals. Br J Psychiatry. 1988 ; 152: 522-534
271. Martenyi F, Brown EB, Zhang H, et al. Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry. 2002 ; 181: 315-320
272. Martin JLR, Sainz-Pardo M, Furukawa TA, et al. Benzodiazepines in generalized anxiety disorder: Heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol. 2007 ; 21: 774-782
273. Martinsen EW, Olsen T, Tonset E, et al. Cognitive-behavioral group therapy for panic disorder in the general clinical setting: A naturalistic study with 1-year follow-up. J Clin Psychiatry. 1998 ; 59: 437-442
274. Mathias S, Fifer S, Mazonson P, et al. Necessary but not sufficient: The effect of screening and feedback on outcomes of primary care patients with untreated anxiety. J Gen Intern Med. 1994 ; 9: 606-615
275. Mayou R, Bryant B, Ehlers A. Prediction of psychological outcomes one year after a motor vehicle accident. Am J Psychiatry. 2001 ; 158: 1231-1238
276. Mbaya P, Alam F, Ashim S, et al. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum Psychopharmacol. 2007 ; 22: 129-133
277. Mead GE, Hsieh C-F, Lee R, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2012 ; 11: CD009286
278. Meibach RC, Dunner D, Wilson LG, et al. Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: A double-blind trial. J Clin Psychiatry. 1987 ; 48: 355-358
279. Merom D, Phongsavan P, Wagner R, et al. Promoting walking as an adjunct intervention to group cognitive behavioral therapy for an anxiety disorders - a pilot group randomized trial. J Anxiety Disord. 2008 ; 22: 959-968
280. Michelson D, Allgulander C, Dantendorfer K, et al. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder - randomised, placebo-controlled trial. Br J Psychiatry. 2001 ; 179: 514-518
281. Michelson D, Lydiard RB, Pollack MH, et al. Outcome assessment and clinical improvement in panic disorder: Evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry. 1998 ; 155: 1570-1577
282. Mihalopoulos C, Kiropoulos L, Shih STF, et al. Exploratory economic analyses of two primary care mental health projects: Implications for sustainability. Med J Aust. 2005 ; 183: S73 - S76
283. Milrod B, Leon AC, Busch F, et al. A randomized controlled clinical trial of psychoanalytic psychotherapy for panic disorder. Am J Psychiatry. 2007 ; 164: 265-272
284. Mithoefer MC, Wagner MT, Mithoefer AT, et al. The safety and efficacy of +/- 3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. J Psychopharmacol. 2011 ; 25: 439-452
285. Mithoefer MC, Wagner MT, Mithoefer AT, et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. J Psychopharmacol. 2013 ; 27: 28-39
286. Monnelly EP, Ciraulo DA, Knapp C, et al. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol. 2003 ; 23: 193-196
287. Montgomery S, Emir B, Haswell H, et al. Long-term treatment of anxiety disorders with pregabalin: A 1 year open-label study of safety and tolerability. Curr Med Res Opin. 2013 ; 29: 1223-1230
288. Montgomery SA, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol. 2004 ; 19: 271-280
289. Montgomery SA, Mahe V, Haudiquet V, et al. Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: Results of a survival analysis. J Clin Psychopharmacol. 2002 ; 22: 561-567
290. Mowla A, Khajeian AM, Sahraian A, et al. Topiramate augmentation in resistant OCD: A double-blind placebo-controlled clinical trial. CNS Spectr. 2010 ; 15: 613-617
291. Muehlbacher M, Nickel MK, Nickel C, et al. Mirtazapine treatment of social phobia in women - A randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005 ; 25: 580-583
292. Mukherjee S, Sullivan G, Perry D, et al. Adherence to treatment among economically disadvantaged patients with panic disorder. Psychiatr Serv. 2006 ; 57: 1745-1750
293. Mukuria C, Brazier J, Barkham M, et al. Cost-effectiveness of an improving access to psychological therapies service. Br J Psychiatry. 2013 ; 202: 220-227
294. Munjack DJ, Crocker B, Cabe D, et al. Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol. 1989 ; 9: 22-27
295. Munk-Jorgensen P, Allgulander C, Dahl AA, et al. Prevalence of generalized anxiety disorder in general practice in Denmark, Finland, Norway, and Sweden. Psychiatr Serv. 2006 ; 57: 1738-1744
296. Muscatello MR, Spina E, Bandelow B, et al. Clinically relevant drug interactions in anxiety disorders. Hum Psychopharmacol. 2012 ; 27: 239-253
297. Nardi AE, Freire RC, Mochcovitch MD, et al. A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol. 2012 ; 32: 120-126
298. NICE clinical guideline 123. Manchester: National Institute for Health and Clinical Excellence ; 2011 :
299. Post-Traumatic Stress Disorder (PTSD): The Management of PTSD in Adults and Children in Primary and Secondary Care. NICE Guideline 26. London: National Institute for Clinical Excellence ; 2005a :
300. Social Anxiety Disorder: Recognition, Assessment and Treatment. NICE Clinical Guideline 159. Manchester: National Institute for Health and Care Excellence ; 2013 :
301. Obsessive-compulsive Disorder: Core Interventions in the Treatment of Obsessive-Compulsive Disorder and Body Dysmorphic Disorder. Clinical Guideline 31. London: National Institute for Health and Clinical Excellence ; 2005b :
302. Depression and Anxiety - Computerised Cognitive Behavioural Therapy (CCBT) (Review of Technology Appraisal 51). London: National Institute for Health and Clinical Excellence ; 2006 :
303. Generalised Anxiety Disorder and Panic Disorder (With or Without Agoraphobia) in Adults: Management in Primary, Secondary and Community Care. NICE Clinical Guideline 113. Manchester: National Institute for Health and Clinical Excellence ; 2011 :
304. Nave AM, Tolin DF, Stevens MC. Exposure therapy, D-cycloserine, and functional magnetic resonance imaging in patients with snake phobia: A randomized pilot study. J Clin Psychiatry. 2012 ; 73: 1179-1186
305. Nease DE, Aikens JE. DSM depression and anxiety criteria and severity of symptoms in primary care: cross sectional study. Brit Med J. 2003 1030-1031 ; 327 :
306. Nemeroff CB, Bremner JD, Foa EB, et al. Posttraumatic stress disorder: A state-of-the-science review. J Psychiatr Res. 2006 ; 40: 1-21
307. Ninan PT, Koran LM, Kiev A, et al. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: A multicenter double-blind tyial. J Clin Psychiatry. 2006 ; 67: 15-22
308. Nugent NR, Christopher NC, Crow JP, et al. The efficacy of early propranolol administration at reducing PTSD symptoms in pediatric injury patients: A pilot study. J Trauma Stress. 2010 ; 23: 282-287
309. Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr. 2005 ; 10: 49-56
310. Nutt DJ, Baldwin DS, Clayton AH, et al. The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry. 2006 ; 67: 46-49
311. O'Brien J, Burns A. Clinical practice with anti-dementia drugs: A revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2011 ; 25: 997-1019
312. Oehen P, Traber R, Widmer V, et al. A randomized, controlled pilot study of MDMA (+/- 3,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). J Psychopharmacol. 2013 ; 27: 40-52
313. Olsson I, Mykletun A, Dahl AA. Recognition and treatment recommendations for generalized anxiety disorder and major depressive episode: A cross-sectional study among general practitioners in norway. Prim Care Companion J Clin Psychiatry. 2006 ; 8: 340-347
314. Ontiveros A, Fontaine R. Sodium valproate and clonazepam for treatment-resistant panic disorder. J Psychiatry Neurosci. 1992 ; 17: 78-80
315. Ormel J, Koeter MWJ, Vandenbrink W, et al. Recognition, management, and course of anxiety and depression in general practice. Arch Gen Psychiatry. 1991 ; 48: 700-706
316. Otto MW, Pollack MH, Penava SJ, et al. Group cognitive-behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: A clinical case series. Behav Res Ther. 1999 ; 37: 763-770
317. Otto MW, Tolin DF, Simon NM, et al. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry. 2010 ; 67: 365-370
318. Oude Voshaar RC. Lack of interventions for anxiety in older people. Br J Psychiatry. 2013 ; 203: 8-9
319. Ougrin D. Efficacy of exposure versus cognitive therapy in anxiety disorders: Systematic review and meta-analysis. BMC Psychiatry. 2011 ; 11: 200
320. Oyebode F, Rastogi A, Berrisford G, et al. Psychotropics in pregnancy: Safety and other considerations. Pharmacol Ther. 2012 ; 135: 71-77
321. Padala PR, Madison J, Monnahan M, et al. Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol. 2006 ; 21: 275-280
322. Pampaloni I, Sivakumaran T, Hawley CJ, et al. High-dose selective serotonin reuptake inhibitors in OCD: A systematic retrospective case notes survey. J Psychopharmacol. 2010 ; 24: 1439-1445
323. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder - A placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004 ; 24: 141-149
324. Parslow R, Morgan AJ, Allen NB, et al. Effectiveness of complementary and self-help treatments for anxiety in children and adolescents. Med J Aust. 2008 ; 188: 355-359
325. Patel SR, Simpson HB. Patient preferences for obsessive-compulsive disorder treatment. J Clin Psychiatry. 2010 ; 71: 1434-1439
326. Perahia DG, Kajdasz DK, Desaiah D, et al. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord. 2005 ; 89: 207-212
327. Perkonigg A, Pfister H, Stein MB, et al. Longitudinal course of posttraumatic stress disorder and posttraumatic stress disorder symptoms in a community sample of adolescents and young adults. Am J Psychiatry. 2005 ; 162: 1320-1327
328. Perna G, Daccò S, Menotti R, et al. Antianxiety medications for the treatment of complex agoraphobia: Pharmacological interventions for a behavioral condition. Neuropsychiatr Dis Treat. 2011 ; 7: 621-637
329. Pilkington K, Kirkwood G, Rampes H, et al. Homeopathy for anxiety and anxiety disorders: A systematic review of the research. Homeopathy. 2006 ; 95: 151-162
330. Pinquart M, Duberstein PR. Treatment of anxiety disorders in older adults: A meta-analytic comparison of behavioral and pharmacological interventions. Am J Geriatr Psychiatry. 2007 ; 15: 639-651
331. Pistrang N, Barker C, Humphreys K. Mutual help groups for mental health problems: A review of effectiveness studies. Am J Community Psychol. 2008 ; 42: 110-121
332. Pitman RK, Sanders KM, Zusman RM, et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry. 2002 ; 51: 189-192
333. Pittenger C, Wasylink S, Coric V. Riluzole augmentation in treatment-refractory OCD: A case series of 13 outpatients, with long-term follow-up. Biol Psychiatry. 2008 ; 63: 178S - 178S
334. Poirier-Bisson J, Roberge P, Marchand A, et al. Studies of cost/effectiveness of pharmacological and psychological treatment of anxiety disorders: A literature review. Sante Ment Que. 2010 ; 35: 129-152
335. Pollack MH, Kornstein SG, Spann ME, et al. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res. 2008 ; 42: 1176-1184
336. Pollack MH, Lepola U, Koponen H, et al. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety. 2007 ; 24: 1-14
337. Pollack MH, Otto MW, Kaspi SP, et al. Cognitive behavior therapy for treatment-refractory panic disorder. J Clin Psychiatry. 1994 ; 55: 200-205
338. Pollack MH, Simon NM, Zalta AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: A placebo controlled study. Biol Psychiatry. 2006 ; 59: 211-215
339. Ponniah K, Hollon SD. Empirically supported psychological interventions for social phobia in adults: A qualitative review of randomized controlled trials. Psychol Med. 2008 ; 38: 3-14
340. Rachman S, Cobb J, Grey S, et al. The behavioural treatment of obsessional-compulsive disorders, with and without clomipramine. Behav Res Ther. 1979 ; 17: 467-478
341. Ramsawh HJ, Raffa SD, Edelen MO, et al. Anxiety in middle adulthood: Effects of age and time on the 14-year course of panic disorder, social phobia and generalized anxiety disorder. Psychol Med. 2009 ; 39: 615-624
342. Raskind MA, Peskind ER, Kanter ED, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: A placebo-controlled study. Am J Psychiatry. 2003 ; 160: 371-373
343. Reich J. Avoidant personality disorder and its relationship to social phobia. Curr Psychiatry Rep. 2009 ; 11: 89-93
344. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy - use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004 ; 61: 1136-1144
345. Ribeiro L, Busnello JV, Kauer-Sant'Anna M, et al. Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res. 2001 ; 34: 1303-1307
346. Rickels K, Etemad B, Khalid-Khan S, et al. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry. 2010 ; 67: 1274-1281
347. Rickels K, Shiovitz TM, Ramey TS, et al. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol. 2012 ; 27: 142-150
348. Rickwood D, Bradford S. The role of self-help in the treatment of mild anxiety disorders in young people: An evidence-based review. Psychol Res Behav Manag. 2012 ; 5: 25-36
349. Rief W, Trenkamp S, Auer C, et al. Cognitive behavior therapy in panic disorder and comorbid major depression - A naturalistic study. Psychother Psychosom. 2000 ; 69: 70-78
350. Robbins JM, Kirmayer LJ, Cathebras P, et al. Physician characteristics and the recognition of depression and anxiety in primary care. Med Care. 1994 ; 32: 795-812
351. Roberge P, Marchand A, Reinharz D, et al. Cognitive-behavioral treatment for panic disorder with agoraphobia - a randomized, controlled trial and cost-effectiveness analysis. Behav Modif. 2008 ; 32: 333-351
352. Roberts NP, Kitchiner NJ, Kenardy J, et al. Multiple session early psychological interventions for the prevention of post-traumatic stress disorder. Cochrane Database Syst Rev. 2009 ; 3: CD006869
353. Robinson J, Sareen J, Cox B, et al. Self-medication of anxiety disorders with alcohol and drugs: Results from a nationally representative sample. J Anxiety Disord. 2009 ; 23: 38-45
354. Robinson J, Sareen J, Cox BJ, et al. Role of self-medication in the development of comorbid anxiety and substance use disorders a longitudinal investigation. Arch Gen Psychiatry. 2011 ; 68: 800-807
355. Rodriguez BF, Weisberg RB, Pagano ME, et al. Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients. J Nerv Ment Dis. 2006 ; 194: 91-97
356. Roness A, Mykletun A, Dahl AA. Help-seeking behaviour in patients with anxiety disorder and depression. Acta Psychiatr Scand. 2005 ; 111: 51-58
357. Rosa-Alcazar AI, Sanchez-Meca J, Gomez-Conesa A, et al. Psychological treatment of obsessive-compulsive disorder: A meta-analysis. Clin Psychol Rev. 2008 ; 28: 1310-1325
358. Ross DC, Klein DF, Uhlenhuth EH. Improved statistical analysis of moclobemide dose effects on panic disorder treatment. Eur Arch Psychiatry Clin Neurosci. 2010 ; 260: 243-248
359. Ross L, McLean L. Anxiety disorders during pregnancy and the postpartum period: A systematic review. J Clin Psychiatry. 2006 ; 67: 1285-1298
360. Rothbaum BO, Davidson JR, Stein DJ, et al. A pooled analysis of gender and trauma-type effects on responsiveness to treatment of PTSD with venlafaxine extended release or placebo. J Clin Psychiatry. 2008a ; 69: 1529-1539
361. Rothbaum BO, Killeen TK, Davidson JR, et al. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. J Clin Psychiatry. 2008b ; 69: 520-525
362. Roy-Byrne P, Craske M, Stein M. Panic disorder. Lancet. 2006 ; 368: 1023-1032
363. Roy-Byrne P, Russo J, Dugdale DC, et al. Undertreatment of panic disorder in primary care: Role of patient and physician characteristics. J Am Board Fam Pract. 2002 ; 15: 443-450
364. Roy-Byrne P, Stang P, Wittchen H, et al. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. Br J Psychiatry. 2000 ; 176: 229-235
365. Roy-Byrne PP, Davidson KW, Kessler RC, et al. Anxiety disorders and comorbid medical illness. Gen Hosp Psychiatry. 2008 ; 30: 208-225
366. Roy-Byrne PP, Stein MB, Russo J, et al. Panic disorder in the primary care setting: Comorbidity, disability, service utilization, and treatment. J Clin Psychiatry. 1999 ; 60: 492-499
367. Use of Licensed Medicines for Unlicensed Applications in Psychiatric Practice. London: Royal College of Psychiatrists ; 2007 :
368. Rubio G, Lopez-Ibor JJ. Generalized anxiety disorder: A 40-year follow-up study. Acta Psychiatr Scand. 2007a ; 115: 372-379
369. Rubio G, Lopez-Ibor JJ. What can be learnt from the natural history of anxiety disorders?. Eur Psychiatry. 2007b ; 22: 80-86
370. Sarris J, LaPorte E, Schweitzer I. Kava: A comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry. 2011a ; 45: 27-35
371. Sarris J, Panossian A, Schweitzer I, et al. Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence. Eur Neuropsychopharmacol. 2011b ; 21: 841-860
372. Schatzberg A, Blier P, Delgado P, et al. Antidepressant discontinuation syndrome: Consensus panel recommendations for clinical management and additional research. J Clin Psychiatry. 2006 ; 67: 27-30
373. Schelling G, Briegel J, Roozendaal B, et al. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors. Biol Psychiatry. 2001 ; 50: 978-985
374. Schelling G, Kilger E, Roozendaal B, et al. Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: A randomized study. Biol Psychiatry. 2004 ; 55: 627-633
375. Schmidt NB, Keogh ME. Treatment of panic. Annu Rev Clin Psychol. 2010 ; 6: 241-256
376. Schneier FR, Neria Y, Pavlicova M, et al. Combined prolonged exposure therapy and paroxetine for PTSD related to the world trade center attack: A randomized controlled trial. Am J Psychiatry. 2012 ; 169: 80-88
377. Schueler YB, Koesters M, Wieseler B, et al. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand. 2011 ; 123: 247-265
378. Schutters SIJ, Van Megen HJGM, Van Veen JF, et al. Mirtazapine in generalized social anxiety disorder: A randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2010 ; 25: 302-304
379. Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry. 2004 ; 65: 244-248
380. Seedat S, van Rheede van Oudtshoorn E, Muller JE, et al. Reboxetine and citalopram in panic disorder: A single-blind, cross-over, flexible-dose pilot study. Int Clin Psychopharmacol. 2003 ; 18: 279-284
381. Seidler GH, Wagner FE. Comparing the efficacy of EMDR and trauma-focused cognitive-behavioral therapy in the treatment of PTSD: A meta-analytic study. Psychol Med. 2006 ; 36: 1515-1522
382. Seivewright H, Green J, Salkovskis P, et al. Randomised controlled trial of cognitive behaviour therapy in the treatment of health anxiety in a genitourinary medicine clinic. Br J Psychiatry. 2008 ; 192: 332-337
383. Sepede G, De Berardis D, Gambi F, et al. Olanzapine augmentation in treatment-resistant panic disorder - a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol. 2006 ; 26: 45-49
384. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants a meta-analysis. J Clin Psychopharmacol. 2009 ; 29: 259-266
385. Shalev AY, Ankri Y, Israeli-Shalev Y, et al. Prevention of posttraumatic stress disorder by early treatment. Arch Gen Psychiatry. 2012 ; 69: 166-176
386. Shalev AY, Freedman S, Peri T, et al. Prospective study of posttraumatic stress disorder and depression following trauma. Am J Psychiatry. 1998 ; 155: 630-637
387. Sheehan DV, Davidson J, Manschreck T, et al. Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol. 1983 ; 3: 28-31
388. Sheehan DV, Raj AB, Sheehan KH, et al. The relative efficacy of buspirone, imipramine and placebo in panic disorder: A preliminary report. Pharmacol Biochem Behav. 1988 ; 29: 815-817
389. Shekelle PG, Woolf SH, Eccles M, et al. Developing guidelines. Brit Med J. 1999 ; 318: 593-596
390. Sherman KJ, Ludman EJ, Cook AJ, et al. Effectiveness of therapeutic massage for generalized anxiety disorder: A randomized controlled trial. Depress Anxiety. 2010 ; 27: 441-450
391. Siegmund A, Golfels F, Finck C, et al. D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res. 2011 ; 45: 1042-1047
392. Simon NM, Connor KM, LeBeau RT, et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: Preliminary findings. Psychopharmacology (Berl). 2008 ; 197: 675-681
393. Simon NM, Otto MW, Worthington JJ, et al. Next-step strategies for panic disorder refractory to initial pharmacotherapy: A 3-phase randomized clinical trial. J Clin Psychiatry. 2009 ; 70: 1563-1570
394. Simon NM, Worthington JJ, Moshier SJ, et al. Duloxetine for the treatment of generalized social anxiety disorder: A preliminary randomized trial of increased dose to optimize response. CNS Spectr. 2010 ; 15: 367-373
395. Simpson HB, Foa EB, Liebowitz MR, et al. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry. 2008 ; 165: 621-630
396. Sinclair LI, Christmas DM, Hood SD, et al. Antidepressant-induced jitteriness/anxiety syndrome: Systematic review. Br J Psychiatry. 2009 ; 194: 483-490
397. Smit F, Willemse G, Meulenbeek P, et al. Preventing panic disorder: Cost-effectiveness analysis alongside a pragmatic randomised trial. Cost Eff Resour Alloc. 2009 ; 7: 8
398. Smolders M, Laurant M, van Rijswijk E, et al. The impact of co-morbidity on GPs' pharmacological treatment decisions for patients with an anxiety disorder. Fam Pract. 2007 ; 24: 538-546
399. Smolders M, Laurant M, Verhaak P, et al. Adherence to evidence-based guidelines for depression and anxiety disorders is associated with recording of the diagnosis. Gen Hosp Psychiatry. 2009 ; 31: 460-469
400. Soltani F, Sayyah M, Feizy F, et al. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum Psychopharmacol. 2010 ; 25: 509-513
401. Soomro GM, Altman D, Rajagopal S, et al. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008 ; 1: CD001765
402. Sørensen P, Birket-Smith M, Wattar U, et al. A randomized clinical trial of cognitive behavioural therapy versus short-term psychodynamic psychotherapy versus no intervention for patients with hypochondriasis. Psychol Med. 2011 ; 41: 431-441
403. Spivak B, Strous RD, Shaked G, et al. Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder - A double-blind, fixed-dosage, controlled trial. J Clin Psychopharmacol. 2006 ; 26: 152-156
404. Stein DJ, Ahokas A, Albarran C, et al. Agomelatine prevents relapse in generalized anxiety disorder: A 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry. 2012 ; 73: 1002-1008
405. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: A randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008a ; 28: 561-566
406. Stein DJ, Andersen EW, Tonnoir B, et al. Escitalopram in obsessive-compulsive disorder: A randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin. 2007a ; 23: 701-711
407. Stein DJ, Baldwin DS, Baldinetti F, et al. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: A pooled analysis of 6 studies. Eur Neuropsychopharmacol. 2008b ; 18: 422-430
408. Stein DJ, Stein MB, Pitts CD, et al. Predictors of response to pharmacotherapy in social anxiety disorder: An analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry. 2002a ; 63: 152-155
409. Stein DJ, Westenberg HGM, Yang HC, et al. Fluvoxamine CR in the long-term treatment of social anxiety disorder: The 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol. 2003 ; 6: 317-323
410. Stein MB, Kerridge C, Dimsdale JE, et al. Pharmacotherapy to prevent PTSD: Results from a randomized controlled proof-of-concept trial in physically injured patients. J Trauma Stress. 2007b ; 20: 923-932
411. Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study. Am J Psychiatry. 2002b ; 159: 1777-1779
412. Stein MB, McQuaid JR, Laffaye C, et al. Social phobia in the primary care medical setting. J Fam Pract. 1999 ; 48: 514-519
413. Stein MB, Sareen J, Hami S, et al. Pindolol potentiation of paroxetine for generalized social phobia: A double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001 ; 158: 1725-1727
414. Stewart SE, Jenike EA, Hezel DM, et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol. 2010 ; 30: 34-39
415. Stinson FS, Dawson DA, Chou SP, et al. The epidemiology of DSM-IV specific phobia in the USA: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2007 ; 37: 1047-1059
416. Stoddard FJ, Luthra R, Sorrentino EA, et al. A randomized controlled trial of sertraline to prevent posttraumatic stress disorder in burned children. J Child Adolesc Psychopharmacol. 2011 ; 21: 469-477
417. Storch EA, Murphy TK, Goodman WK, et al. A preliminary study of d-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry. 2010 ; 68: 1073-1076
418. Strawn JR, Keeshin BR, DelBello MP, et al. Psychopharmacologic treatment of posttraumatic stress disorder in children and adolescents: A review. J Clin Psychiatry. 2010 ; 71: 932-941
419. Strombom I, Wernicke JF, Seeger J, et al. Hepatic effects of duloxetine-III: Analysis of hepatic events using external data sources. Curr Drug Saf. 2008 ; 3: 154-162
420. Tart CD, Handelsman PR, Deboer LB, et al. Augmentation of exposure therapy with post-session administration of D-cycloserine. J Psychiatr Res. 2013 ; 47: 168-174
421. Tenneij NH, van Megen H, Denys D, et al. Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. J Clin Psychiatry. 2005 ; 66: 1169-1175
422. Terluin B, Brouwers EPM, van Marwijk HWJ, et al. Detecting depressive and anxiety disorders in distressed patients in primary care; comparative diagnostic accuracy of the Four-Dimensional Symptom Questionnaire (4DSQ) and the Hospital Anxiety and Depression Scale (HADS). BMC Family Practice. 2009 ; 10: 58
423. Thanacoody HKR, Thomas SHL. Tricyclic antidepressant poisoning: Cardiovascular toxicity. Toxicol Rev. 2005 ; 24: 205-214
424. Thase ME. Effects of venlafaxine on blood pressure: A meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998 ; 59: 502-508
425. Thomson AB, Page LA. Psychotherapies for hypochondriasis. Cochrane Database Syst Rev. 2007 ;: CD006520
426. Thorp SR, Ayers CR, Nuevo R, et al. Meta-analysis comparing different behavioral treatments for late-life anxiety. Am J Geriatr Psychiatry. 2009 ; 17: 105-115
427. Tiffon L, Coplan JD, Papp LA, et al. Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. J Clin Psychiatry. 1994 ; 55: 66-69
428. Tiller JW, Bouwer C, Behnke K. Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci. 1999 ; 249: S7 - S10
429. Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: A randomised study. J Psychopharmacol. 2008 ; 22: 330-332
430. Titov N, Andrews G, Johnston L, et al. Shyness programme: Longer term benefits, cost-effectiveness, and acceptability. Aust N Z J Psychiatry. 2009 ; 43: 36-44
431. Tolin DF, Diefenbach GJ, Gilliam CM. Stepped care versus standard cognitive-behavioral therapy for obsessive-compulsive disorder: A preliminary study of efficacy and costs. Depress Anxiety. 2011 ; 28: 314-323
432. Tollefson GD, Birkett M, Koran L, et al. Continuation treatment of OCD: Double-blind and open-label experience with fluoxetine. J Clin Psychiatry. 1994 ; 55: 69-78
433. Toneatto T, Nguyen L. Does mindfulness meditation therapy improve anxiety and mood symptoms? A review of the controlled research. Can J Psychiatry. 2007 ; 52: 260-266
434. Torres AR, Prince MJ, Bebbington PE, et al. Treatment seeking by individuals with obsessive-compulsive disorder from the British Psychiatric Morbidity Survey of 2000. Psychiatr Serv. 2007 ; 58: 977-982
435. Tumur I, Kaltenthaler E, Ferriter M, et al. Computerised cognitive behaviour therapy for obsessive-compulsive disorder: A systematic review. Psychother Psychosom. 2007 ; 76: 196-202
436. Tyrer P, Cooper S, Salkovskis P, et al. Clinical and cost-effectiveness of cognitive behaviour therapy for health anxiety in medical patients: A multicentre randomised controlled trial. Lancet. 2014 ; 383: 219-225
437. Tyrer P, Seivewright H, Johnson T. The Nottingham Study of Neurotic Disorder: Predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder. Psychol Med. 2004 ; 34: 1385-1394
438. US Food and Drug Administration (2012) Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available at: www.fda.gov/Drugs/DrugSafety/ucm269086.htm (accessed 23 July 2013).
439. Vaiva G, Ducrocq F, Jezequel K, et al. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry. 2003 ; 54: 947-949
440. Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord. 1996 ; 39: 115-121
441. Van Apeldoorn FJ, Timmerman ME, Mersch PPA, et al. A randomized trial of cognitive-behavioral therapy or selective serotonin reuptake inhibitor or both combined for panic disorder with or without agoraphobia: Treatment results through 1-year follow-up. J Clin Psychiatry. 2010 ; 71: 574-586
442. Van Boeijen C, van Balkom A, van Oppen P, et al. Efficacy of self-help manuals for anxiety disorders in primary care: A systematic review. Fam Pract. 2005 ; 22: 192-196
443. Van der Watt G, Laugharne J, Janca A. Complementary and alternative medicine in the treatment of anxiety and depression. Curr Opin Psychiatry. 2008 ; 21: 37-42
444. Van Emmerik AAP, Kamphuis JH, Hulsbosch AM, et al. Single session debriefing after psychological trauma: A meta-analysis. Lancet. 2002 ; 360: 766-771
445. Van Rijswijk E, Lucassen P, van De Lisdonk E, et al. Do co-existing psychosocial problems influence the prescription of psychotropic medication in depressive and anxiety disorders?. Eur J Gen Pract. 2006 ; 12: 37-39
446. Van Rijswijk E, van Hout H, van de Lisdonk E, et al. Barriers in recognising, diagnosing and managing depressive and anxiety disorders as experienced by Family Physicians; a focus group study. BMC Family Practice. 2009 ;: 10
447. Vera-Llonch M, Dukes E, Rejas J, et al. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: Findings from a Spanish perspective. Eur J Health Econ. 2010 ; 11: 35-44
448. Verhaak PFM, Schellevis FG, Nuijen J, et al. Patients with a psychiatric disorder in general practice: Determinants of general practitioners' psychological diagnosis. Gen Hosp Psychiatry. 2006 ; 28: 125-132
449. Vermani M, Marcus M, Katzman MA. Rates of detection of mood and anxiety disorders in primary care: A descriptive, cross-sectional study. Prim Care Companion CNS Disord. 2011 ; 13 ( 2 ):
450. Vieweg WVR, Wood MA, Fernandez A, et al. Proarrhythmic risk with antipsychotic and antidepressant drugs implications in the elderly. Drugs Aging. 2009 ; 26: 997-1012
451. Vøllestad J, Nielsen M, Nielsen G. Mindfulness- and acceptance-based interventions for anxiety disorders: A systematic review and meta-analysis. Br J Clin Psychol. 2012 ; 51: 239-260
452. Wade AG, Lepola U, Koponen HJ, et al. The effect of citalopram in panic disorder. Br J Psychiatry. 1997 ; 170: 549-553
453. Wagner AW, Bystritsky A, Russo JE, et al. Beliefs about psychotropic medication and psychotherapy among primary care patients with anxiety disorders. Depress Anxiety. 2005 ; 21: 99-105
454. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008 ; 359: 2753-2766
455. Walkup JT, Labellarte MJ, Riddle MA, et al. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med. 2001 ; 344: 1279-1285
456. Watanabe N, Churchill R, Furukawa TA. Combination of psychotherapy and benzodiazepines versus either therapy alone for panic disorder: A systematic review. BMC Psychiatry. 2007 ; 7: 18
457. Watanabe N, Omori IM, Nakagawa A, et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2011 ;: CD006528
458. Watson HJ, Rees CS. Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder. J Child Psychol Psychiatry. 2008 ; 49: 489-498
459. Wedekind D, Broocks A, Weiss N, et al. A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder. World J Biol Psychiatry. 2010 ; 11: 904-913
460. Weiller E, Bisserbe C, Boyer P, et al. Social phobia in general health care - an unrecognised undertreated disabling disorder. Br J Psychiatry. 1996 ; 168: 169-174
461. Weiller E, Bisserbe JC, Maier W, et al. Prevalence and recognition of anxiety syndromes in five European primary care settings. A report from the WHO study on Psychological Problems in General Health Care. Br J Psychiatry. 1998 ;: 18-23
462. Weisberg RB, Dyck I, Culpepper L, et al. Psychiatric treatment in primary care patients with anxiety disorders: A comparison of care received from primary care providers and psychiatrists. Am J Psychiatry. 2007 ; 164: 276-282
463. Wensel TM, Powe KW, Cates ME. Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother. 2012 ; 46: 424-429
464. Wernicke J, Acharya N, Strombom I, et al. Hepatic effects of duloxetine-II: Spontaneous reports and epidemiology of hepatic events. Curr Drug Saf. 2008a ; 3: 143-153
465. Wernicke J, Pangallo B, Wang F, et al. Hepatic effects of duloxetine-I: Non-clinical and clinical trial data. Curr Drug Saf. 2008b ; 3: 132-142
466. White N, Litovitz T, Clancy C. Suicidal antidepressant overdoses: A comparative analysis by antidepressant type. J Med Toxicol. 2008 ; 4: 238-250
467. Wilhelm S, Buhlmann U, Tolin DF, et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008 ; 165: 335-341
468. Wilson S, Nutt D, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010 ; 24: 1577-1601
469. Wittchen H, Gloster A, Beesdo-Baum K, et al. Agoraphobia: A review of the diagnostic classificatory position and criteria. Depress Anxiety. 2010 ; 27: 113-133
470. Wittchen HU, Carter RM, Pfister H, et al. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol. 2000 ; 15: 319-328
471. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe - a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol. 2005 ; 15: 357-376
472. Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 ; 21: 655-679
473. Wittchen HU, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: Prevalence, recognition, and management. J Clin Psychiatry. 2002 ; 63: 24-34
474. Woelk H, Schlaefke S. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine. 2010 ; 17: 94-99
475. Wolitzky-Taylor KB, Castriotta N, Lenze EJ, et al. Anxiety disorders in older adults: A comprehensive review. Depress Anxiety. 2010 ; 27: 190-211
476. Wolitzky-Taylor KB, Horowitz JD, Powers MB, et al. Psychological approaches in the treatment of specific phobias: A meta-analysis. Clin Psychol Rev. 2008 ; 28: 1021-1037
477. Wong N, Sarver DE, Beidel DC. Quality of life impairments among adults with social phobia: The impact of subtype. J Anxiety Disord. 2012 ; 26: 50-57
478. Wood DP, Murphy J, McLay R, et al. Cost effectiveness of virtual reality graded exposure therapy with physiological monitoring for the treatment of combat related post traumatic stress disorder. Stud Health Technol Inform. 2009 ; 144: 223-229
479. Woolf AD, Erdman AR, Nelson LS, et al. Tricyclic antidepressant poisoning: An evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2007 ; 45: 203-233
480. ICD-10 Classification of Mental and Behavioural Disorders. Geneva: World Health Organization ; 1992 :
481. Yeh MSL, Mari JJ, Pupo Costa MC, et al. A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neurosci Ther. 2011 ; 17: 305-310
482. Zaudig M. Heterogeneity and comorbidity of obsessive-compulsive disorder. Nervenarzt. 2011 ; 82: 290-294
483. Ziedonis D, Hitsman B, Beckham JC, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res. 2008 ; 10: 1691-1715
484. Zivin K, Pfeiffer P, Bohnert A, et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry. 2013 ; 170: 642-650
485. Zoellner LA, Feeny NC, Bittinger JN. What you believe is what you want: Modeling PTSD-related treatment preferences for sertraline or prolonged exposure. J Behav Ther Exp Psychiatry. 2009 ; 40: 455-467
486. Zohar J, Yahalom H, Kozlovsky N, et al. High dose hydrocortisone immediately after trauma may alter the trajectory of PTSD: Interplay between clinical and animal studies. Eur Neuropsychopharmacol. 2011 ; 21: 796-809